Molecular Profile of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a relatively uncommon but highly aggressive primary liver cancer that originates within the liver. The aim of this study is to review the molecular profile of intrahepatic cholangiocarcinoma and its implications for prognostication and decision-making. This c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/1/461 |
| _version_ | 1797358642381455360 |
|---|---|
| author | Wellington Andraus Francisco Tustumi José Donizeti de Meira Junior Rafael Soares Nunes Pinheiro Daniel Reis Waisberg Liliana Ducatti Lopes Rubens Macedo Arantes Vinicius Rocha Santos Rodrigo Bronze de Martino Luiz Augusto Carneiro D’Albuquerque |
| author_facet | Wellington Andraus Francisco Tustumi José Donizeti de Meira Junior Rafael Soares Nunes Pinheiro Daniel Reis Waisberg Liliana Ducatti Lopes Rubens Macedo Arantes Vinicius Rocha Santos Rodrigo Bronze de Martino Luiz Augusto Carneiro D’Albuquerque |
| author_sort | Wellington Andraus |
| collection | DOAJ |
| description | Intrahepatic cholangiocarcinoma (ICC) is a relatively uncommon but highly aggressive primary liver cancer that originates within the liver. The aim of this study is to review the molecular profile of intrahepatic cholangiocarcinoma and its implications for prognostication and decision-making. This comprehensive characterization of ICC tumors sheds light on the disease’s underlying biology and offers a foundation for more personalized treatment strategies. This is a narrative review of the prognostic and therapeutic role of the molecular profile of ICC. Knowing the molecular profile of tumors helps determine prognosis and support certain target therapies. The molecular panel in ICC helps to select patients for specific therapies, predict treatment responses, and monitor treatment responses. Precision medicine in ICC can promote improvement in prognosis and reduce unnecessary toxicity and might have a significant role in the management of ICC in the following years. The main mutations in ICC are in <i>tumor protein p53</i> (<i>TP53</i>), <i>Kirsten rat sarcoma virus</i> (<i>KRAS</i>), <i>isocitrate dehydrogenase 1</i> (<i>IDH1</i>), and <i>AT-rich interactive domain-containing protein 1A</i> (<i>ARID1A</i>). The rate of mutations varies significantly for each population. Targeting <i>TP53</i> and <i>KRAS</i> is challenging due to the natural characteristics of these genes. Different stages of clinical studies have shown encouraging results with inhibitors of mutated <i>IDH1</i> and target therapy for <i>ARID1A</i> downstream effectors. <i>Fibroblast growth factor receptor 2</i> (<i>FGFR2</i>) fusions are an important target in patients with ICC. Immune checkpoint blockade can be applied to a small percentage of ICC patients. Molecular profiling in ICC represents a groundbreaking approach to understanding and managing this complex liver cancer. As our comprehension of ICC’s molecular intricacies continues to expand, so does the potential for offering patients more precise and effective treatments. The integration of molecular profiling into clinical practice signifies the dawn of a new era in ICC care, emphasizing personalized medicine in the ongoing battle against this malignancy. |
| first_indexed | 2024-03-08T15:04:59Z |
| format | Article |
| id | doaj.art-0e5d12d58df7466d9ce8a057abbbe8fc |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T15:04:59Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-0e5d12d58df7466d9ce8a057abbbe8fc2024-01-10T14:59:36ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-12-0125146110.3390/ijms25010461Molecular Profile of Intrahepatic CholangiocarcinomaWellington Andraus0Francisco Tustumi1José Donizeti de Meira Junior2Rafael Soares Nunes Pinheiro3Daniel Reis Waisberg4Liliana Ducatti Lopes5Rubens Macedo Arantes6Vinicius Rocha Santos7Rodrigo Bronze de Martino8Luiz Augusto Carneiro D’Albuquerque9Department of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilDepartment of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo 05403-000, BrazilIntrahepatic cholangiocarcinoma (ICC) is a relatively uncommon but highly aggressive primary liver cancer that originates within the liver. The aim of this study is to review the molecular profile of intrahepatic cholangiocarcinoma and its implications for prognostication and decision-making. This comprehensive characterization of ICC tumors sheds light on the disease’s underlying biology and offers a foundation for more personalized treatment strategies. This is a narrative review of the prognostic and therapeutic role of the molecular profile of ICC. Knowing the molecular profile of tumors helps determine prognosis and support certain target therapies. The molecular panel in ICC helps to select patients for specific therapies, predict treatment responses, and monitor treatment responses. Precision medicine in ICC can promote improvement in prognosis and reduce unnecessary toxicity and might have a significant role in the management of ICC in the following years. The main mutations in ICC are in <i>tumor protein p53</i> (<i>TP53</i>), <i>Kirsten rat sarcoma virus</i> (<i>KRAS</i>), <i>isocitrate dehydrogenase 1</i> (<i>IDH1</i>), and <i>AT-rich interactive domain-containing protein 1A</i> (<i>ARID1A</i>). The rate of mutations varies significantly for each population. Targeting <i>TP53</i> and <i>KRAS</i> is challenging due to the natural characteristics of these genes. Different stages of clinical studies have shown encouraging results with inhibitors of mutated <i>IDH1</i> and target therapy for <i>ARID1A</i> downstream effectors. <i>Fibroblast growth factor receptor 2</i> (<i>FGFR2</i>) fusions are an important target in patients with ICC. Immune checkpoint blockade can be applied to a small percentage of ICC patients. Molecular profiling in ICC represents a groundbreaking approach to understanding and managing this complex liver cancer. As our comprehension of ICC’s molecular intricacies continues to expand, so does the potential for offering patients more precise and effective treatments. The integration of molecular profiling into clinical practice signifies the dawn of a new era in ICC care, emphasizing personalized medicine in the ongoing battle against this malignancy.https://www.mdpi.com/1422-0067/25/1/461tumor biomarkerscholangiocarcinomaliver neoplasms |
| spellingShingle | Wellington Andraus Francisco Tustumi José Donizeti de Meira Junior Rafael Soares Nunes Pinheiro Daniel Reis Waisberg Liliana Ducatti Lopes Rubens Macedo Arantes Vinicius Rocha Santos Rodrigo Bronze de Martino Luiz Augusto Carneiro D’Albuquerque Molecular Profile of Intrahepatic Cholangiocarcinoma International Journal of Molecular Sciences tumor biomarkers cholangiocarcinoma liver neoplasms |
| title | Molecular Profile of Intrahepatic Cholangiocarcinoma |
| title_full | Molecular Profile of Intrahepatic Cholangiocarcinoma |
| title_fullStr | Molecular Profile of Intrahepatic Cholangiocarcinoma |
| title_full_unstemmed | Molecular Profile of Intrahepatic Cholangiocarcinoma |
| title_short | Molecular Profile of Intrahepatic Cholangiocarcinoma |
| title_sort | molecular profile of intrahepatic cholangiocarcinoma |
| topic | tumor biomarkers cholangiocarcinoma liver neoplasms |
| url | https://www.mdpi.com/1422-0067/25/1/461 |
| work_keys_str_mv | AT wellingtonandraus molecularprofileofintrahepaticcholangiocarcinoma AT franciscotustumi molecularprofileofintrahepaticcholangiocarcinoma AT josedonizetidemeirajunior molecularprofileofintrahepaticcholangiocarcinoma AT rafaelsoaresnunespinheiro molecularprofileofintrahepaticcholangiocarcinoma AT danielreiswaisberg molecularprofileofintrahepaticcholangiocarcinoma AT lilianaducattilopes molecularprofileofintrahepaticcholangiocarcinoma AT rubensmacedoarantes molecularprofileofintrahepaticcholangiocarcinoma AT viniciusrochasantos molecularprofileofintrahepaticcholangiocarcinoma AT rodrigobronzedemartino molecularprofileofintrahepaticcholangiocarcinoma AT luizaugustocarneirodalbuquerque molecularprofileofintrahepaticcholangiocarcinoma |